FEIBA® in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: A retrospective survey in regional haemophilia centre

Haemophilia

Volumn 15, Issue 3, 2009, Pages 743-751

  Smejkal, Petr ^a   Brabec, P ^b   Matyskova, M ^a   Bulikova, A ^a   Slechtova, M ^a   Kissova, J ^a   Chlupova, G ^a   Muzik, J ^b   Penka, M ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Bleeding; Efficacy; FEIBA; Haemophilia; Inhibitors; Treatment

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AUTOPLEX T; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR;

ACUTE DISEASE; ADULT; ANTIBODY TITER; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; DISEASE SURVEILLANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEMARTHROSIS; HEMATURIA; HEMOPHILIA A; HOME CARE; HUMAN; LOW DRUG DOSE; MUSCLE BLEEDING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RECURRENT DISEASE; THROMBOEMBOLISM; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ECONOMICS; HEMOSTASIS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HEMOSTASIS; HOME CARE SERVICES; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65449161303     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02012.x     Document Type: Article

References (32)

1. Astenmark J, Morado M, Rocino A et al. Current European practise in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363-71.
2. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-35.
3. DiMichele D, Negrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12: 352-62.
4. Kurczynski EM, Penner JA. Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med 1974; 291: 164-7.
5. Mehta R, Parameswaran R, Shapiro AD. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents. Haemophilia 2006; 12(Suppl. 6): 54-61.
6. Hilgartner MW, Knatterud GL, the FEIBA Study Group. The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-40.
7. Negrier C, Gomperts ED, Oldenburg J. The history of FEIBA: A lifetime of success in the treatment of haemophilia complicated by an inhibitor. Haemophilia 2006; 12(Suppl. 5): 4-13.
8. Negrier C, Goudemand J, Sultan Y et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997; 77: 1113-9.
9. Hilgartner M, Aledort L, Andes A, Gill J, the members of the FEIBA Study Group. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. Transfusion 1990 ; 30: 626-30.
10. Negrier C, Dargaud Y, Bordet JC. Basic aspects of bypassing agents. Haemophilia 2006; 12(Suppl. 6): 48-53.
11. Dargaud Y, Lambert T, Trossaert M. New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors. Haemophilia 2008; 14(Suppl. 4): 20-7.
12. Teitel J, Berntorp E, Collins P et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13: 256-63.
13. Astenmark J, Rocino A, von Depka M et al. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia 2007; 13: 38-45.
14. Kavakli K, Makris M, Zulfikar B, Erhardsten E, Abrams ZS, Kenet G. NovoSeven trial (F7HEAM-1510) investigators. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95: 600-5.
15. Santagostino E, Mancuso ME, Rocino A et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71.
16. Astenmark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
17. Schneiderman J, Rubin E, Nugent DJ, Zouny G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: Update of our previous experience. Haemophilia 2007; 13: 244-8.
18. Barrowcliffe TW. Monitoring inhibitor patients with the right assays. Semin Hematol 2008; 45(Suppl. 1): 25-30.
19. van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: Are we there yet? Br J Haematol 2008; 142: 889-903.
20. HemIs registry website: Available at https://trials.cba.muni.cz/trialdb/ interface_forms/trialdb.asp?name=starttrialdb_hemis (last accessed on 3 July 2008).
21. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 24: 717-21.
22. Negrier C, the French FEIBA Study Group. FEIBA VH in home treatment -a 3-year prospective experience. Haemophilia 1998; 4: 238. (Abstract 330).
23. De Biasi R, Rocino A, Papa M, Salerno E, Ziello L, Carola A. Treatment of patients with high titer inhibitors to factor VIII: A large experience with the use of an activated prothrombin complex concentrate. Haemophilia 1996; 2: 31. (Abstract 120).
24. Glomstein A, Gronhaug S, Tjonnfjord G. Home treatment with FEIBA®, the Norwegian experience. Haemophilia 2002; 8: 540-1. (Abstract 12 PO 33).
25. Zulfikar B, Aydogan G, Salcioglu Z et al. A Turkish multicenter retrospective study on the efficacy and safety of FEIBA in patients with hemophilia and inhibitors or other rare bleeding disorders. Haemophilia 2008; 14(Suppl. 2): 54. (Abstract 08 PO 75).
26. -1 -dose rFVIIa and aPCC for home treatment of joint bleeds in haemophilia patients with inhibitors: A randomised comparison. Haemophilia 2008; 14: 287-94.
27. Smejkal P, Muzik J, Penka M et al. The use of FEIBA and NOVOSEVEN for treatment of bleeding episodes in patients with hemophilia A and factor VIII inhibitor: A single centre experience. Haematologica 2006; 91(Suppl. 1): 156-7. (Abstract 0427).
28. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
29. Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol 1998; 61(Suppl. 63): 7-10.
30. Santagostino E, Gringeri A, Mannucci PM. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: The advantages of early intervention. Br J Haematol 1999; 104: 22-6.
31. Luu H, Ewenstein B. FEIBA® safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004; 10(Suppl. 2): 10-6.
32. Gomperts ED. FEIBA safety and tolerability profile. Haemophilia 2006; 12(Suppl. 5): 14-9.